Jove
Visualize
Contact Us

Related Experiment Videos

[New methods in insulin treatment].

Gyula Neuwirth1

  • 1Hajdú-Bihar Megyei Onkormányzat Kenézy Gyula Kórház-Rendelointézet, I. Belgyógyászati Osztály, Debrecen.

Orvosi Hetilap
|February 8, 2005
PubMed
Summary

Insulin glargine offers effective basal insulin therapy, reducing hypoglycemia compared to neutral protamin Hagedorn (NPH) insulin. Continuous subcutaneous insulin infusion (CSII) via pump therapy further improves glycemic control and decreases hypoglycemia frequency.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Effectiveness of cardiometabolic risk reduction in patients with type 1 diabetes mellitus].

Orvosi hetilap·2008
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Endocrinology
  • Pharmacology

Context:

  • Basal insulin therapy aims to mimic endogenous insulin secretion for diabetes management.
  • Neutral protamin Hagedorn (NPH) insulin is commonly used but lacks a physiological absorption profile.
  • Newer insulin analogs like insulin glargine offer extended action and improved profiles.

Purpose:

  • To compare the efficacy and safety of insulin glargine with NPH insulin for basal insulin therapy.
  • To review the role and outcomes of continuous subcutaneous insulin infusion (CSII) pump therapy in intensive diabetes management.

Summary:

  • Insulin glargine, an extended-action analog, provides slow absorption and a sustained 24-30 hour concentration profile, reducing hypoglycemia incidence compared to NPH insulin.
  • Insulin glargine demonstrates comparable efficacy to NPH insulin when administered once or twice daily, regardless of timing (breakfast, dinner, bedtime).
  • Continuous subcutaneous insulin infusion (CSII) pump therapy is an intensive approach associated with improved glycemic control and significantly reduced rates of mild and severe hypoglycemia.

Impact:

  • Insulin glargine provides a more predictable basal insulin option with a lower risk of hypoglycemia.
  • CSII pump therapy represents an effective strategy for achieving better glycemic targets and enhancing patient safety in diabetes care.

Related Experiment Videos